Literature DB >> 2692658

Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease.

S Erickson-Viitanen1, J Manfredi, P Viitanen, D E Tribe, R Tritch, C A Hutchison, D D Loeb, R Swanstrom.   

Abstract

The virally encoded protease of human immunodeficiency virus is responsible for the processing of the gag and gag-pol polyprotein precursors to their mature polypeptides. Since correct processing of the viral polypeptides is essential for the production of infectious virus, HIV protease represents a potential target for therapeutic agents that may prove beneficial in the treatment of AIDS. In this study, full-length gag polyprotein has been synthesized in vitro to serve as a substrate for bacterially expressed HIV-1 protease. Expression of the protease in E. coli from the lac promoter was enhanced approximately five-fold by deletion of a potential hairpin loop upstream from the codon determining the amino terminus of mature protease. Extracts of induced cultures of E. coli harboring a protease-containing plasmid served as the source of protease activity. The gag polyprotein synthesized in vitro was cleaved by such lysates, producing fragments corresponding in size to p17 plus p24 and mature p24. Immunoprecipitations with monoclonal antibodies to p17 and p24 polypeptides suggest that initial cleavage of gag polyprotein occurs near the p24-p15 junction. The proteolysis was inhibited by pepstatin with an IC50 of 0.15 mM for cleavage at the p24-p15 junction and 0.02 mM for cleavage at the p17-p24 junction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2692658     DOI: 10.1089/aid.1989.5.577

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  84 in total

1.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Solid-state NMR spectroscopy of protein complexes.

Authors:  Shangjin Sun; Yun Han; Sivakumar Paramasivam; Si Yan; Amanda E Siglin; John C Williams; In-Ja L Byeon; Jinwoo Ahn; Angela M Gronenborn; Tatyana Polenova
Journal:  Methods Mol Biol       Date:  2012

4.  Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer.

Authors:  Y S Cheng; F H Yin; S Foundling; D Blomstrom; C A Kettner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group.

Authors:  Christopher J Bungard; Peter D Williams; Jeanine E Ballard; David J Bennett; Christian Beaulieu; Carolyn Bahnck-Teets; Steve S Carroll; Ronald K Chang; David C Dubost; John F Fay; Tracy L Diamond; Thomas J Greshock; Li Hao; M Katharine Holloway; Peter J Felock; Jennifer J Gesell; Hua-Poo Su; Jesse J Manikowski; Daniel J McKay; Mike Miller; Xu Min; Carmela Molinaro; Oscar M Moradei; Philippe G Nantermet; Christian Nadeau; Rosa I Sanchez; Tummanapalli Satyanarayana; William D Shipe; Sanjay K Singh; Vouy Linh Truong; Sivalenka Vijayasaradhi; Catherine M Wiscount; Joseph P Vacca; Sheldon N Crane; John A McCauley
Journal:  ACS Med Chem Lett       Date:  2016-05-09       Impact factor: 4.345

6.  The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Ferri Soheilian; Kunio Nagashima; Eric O Freed
Journal:  Virology       Date:  2010-02-20       Impact factor: 3.616

7.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity.

Authors:  Wei Wang; Nada Naiyer; Mithun Mitra; Jialin Li; Mark C Williams; Ioulia Rouzina; Robert J Gorelick; Zhengrong Wu; Karin Musier-Forsyth
Journal:  Nucleic Acids Res       Date:  2014-05-09       Impact factor: 16.971

10.  Effect of linker insertion mutations in the human immunodeficiency virus type 1 gag gene on activation of viral protease expressed in bacteria.

Authors:  J Luban; C Lee; S P Goff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.